Arcoma AB

OM:ARCOMA Stock Report

Market Cap: SEK 138.4m

Arcoma Valuation

Is ARCOMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ARCOMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ARCOMA (SEK10.5) is trading below our estimate of fair value (SEK22.79)

Significantly Below Fair Value: ARCOMA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARCOMA?

Key metric: As ARCOMA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ARCOMA. This is calculated by dividing ARCOMA's market cap by their current earnings.
What is ARCOMA's PE Ratio?
PE Ratio10.7x
EarningsSEK 12.98m
Market CapSEK 138.45m

Price to Earnings Ratio vs Peers

How does ARCOMA's PE Ratio compare to its peers?

The above table shows the PE ratio for ARCOMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.5x
MCLR Medclair
44.4xn/aSEK 110.1m
CARE Careium
16.4x16.5%SEK 710.3m
CRAD B C-Rad
15.9x27.4%SEK 920.0m
ADDV A ADDvise Group
21.6x19.2%SEK 853.6m
ARCOMA Arcoma
10.7x7.9%SEK 138.4m

Price-To-Earnings vs Peers: ARCOMA is good value based on its Price-To-Earnings Ratio (10.7x) compared to the peer average (24.6x).

Price to Earnings Ratio vs Industry

How does ARCOMA's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ARCOMA 10.7xIndustry Avg. 28.9xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ARCOMA is good value based on its Price-To-Earnings Ratio (10.7x) compared to the European Medical Equipment industry average (28.9x).

Price to Earnings Ratio vs Fair Ratio

What is ARCOMA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARCOMA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.7x
Fair PE Ratio13.8x

Price-To-Earnings vs Fair Ratio: ARCOMA is good value based on its Price-To-Earnings Ratio (10.7x) compared to the estimated Fair Price-To-Earnings Ratio (13.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Dignitana

SEK 85.4m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.06

7D

-1.9%

1Y

-49.5%

Iconovo

SEK 81.5m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 5.12

7D

-0.8%

1Y

-44.8%

Getinge

SEK 46.6b

Provides products and solutions for operating rooms, intensive-care units, and sterilization departments.

GETI B

SEK 171.10

7D

-6.9%

1Y

-21.8%